Mesalazine-induced psoriasis in patients with inflammatory bowel diseases

ejd.2011.1438 Auteur(s) : Antonella DI CESARE, Rosaria FIDANZA, Assunta RIITANO, Maria Concetta FARGNOLI, Ketty PERIS ketty.peris@univaq.it Department of Dermatology, University of L’Aquila, Via Vetoio-Coppito 2, 67100 L’Aquila, Italy Mesalazine is an aminosalycilate drug approved for the treatment of the active phase of mild-to-moderate inflammatory bowel diseases (IBD) – ulcerative colitis (UC) and Crohn's disease (CD) – and for the prevention of IBD recurrence [1]. The use of mesalazine [...]